Predicting the Effect of Accelerated Fractionation in Postoperative Radiotherapy for Head and Neck Cancer Based on Molecular Marker Profiles: Data From a Randomized Clinical Trial

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 438-446

  Suwinski, Rafal ^a   Jaworska, Magdalena ^a   Nikiel, Barbara ^a   Grzegorz, Wozniak ^a   Bankowska Wozniak, Magdalena ^b   Wojciech, Majewski ^a   Krzysztof, Skladowski ^a   Dariusz, Lange ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Regional Oncology Centre Bydgoszcz   (Poland)

Author keywords

Accelerated postoperative radiotherapy; Head and neck cancer; Molecular markers; Predictive factors; Randomized clinical trial

Indexed keywords

HEAD-AND-NECK CANCER; MOLECULAR MARKER; POSTOPERATIVE RADIOTHERAPY; PREDICTIVE FACTORS; RANDOMIZED CLINICAL TRIALS;

RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

EXPERIMENTS;

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PROTEIN P53;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MOUTH CANCER; OROPHARYNX CANCER; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; OROPHARYNGEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77951966714     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.021     Document Type: Article

References (24)

1. Suwinski R., Bankowska-Wozniak M., Majewski W., et al. Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer. Radiother Oncol 87 (2008) 155-163
2. Ang K.K., Trotti A., Brown B.W., et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51 (2001) 571-578
3. Awwad H.K., Lotayef M., Shouman T., et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: Influence of proliferation. Br J Cancer 86 (2002) 517-523
4. Sanguineti G., Richetti A., Bignardi M., et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys 61 (2005) 762-771
5. Peters L.J., Goepfert H., Ang K.K., et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26 (1993) 3-11
6. Cooper J.S., Pajak T.F., Forastiere A., et al. Precisely defining high-risk operable head and neck tumors based on RTOG 85-03 and 88-24: Targets for postoperative radiochemotherapy?. Head Neck 20 (1998) 588-594
7. Suwinski R., Sowa A., Rutkowski T., et al. Time factor in postoperative radiotherapy: A multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 56 (2003) 399-412
8. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 15 (2002) 7350-7356
9. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 20 (2005) 5560-5577
10. Eriksen J.G., and Steiniche T. Overgaard J for the Danish Head and Neck Cancer study group (DAHANCA). The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74 (2005) 93-100
11. Eriksen J.G., and Steiniche T. Overgaard J for the Danish Head and Neck Cancer study group (DAHANCA). The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol 44 (2005) 50-58
12. Pavelić K., Kapitanović S., Radosevic S., et al. Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis. J Mol Med 78 (2000) 111-118
13. McDonald J.S., Gartside P.S., Pavelic L.J., Gluckman J.L., and Pavelic Z.P. nm23-H1 expression in squamous cell carcinoma of the head and neck. Pathol Oncol Res 2 (1996) 34-36
14. Wang Y.F., Chow K.C., et al. Prognostic significance of nm23-H1 expression in oral squamous cell carcinoma. Br J Cancer 90 (2004) 2186-2193
15. Soslow R.A., Danneberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 89 (2000) 2637-2645
16. Chen W.C., McBride W.H., Chen S.M., et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: Clinical and in vitro studies. Head Neck 27 (2005) 503-512
17. Bernstein D., and Lagakos S.W. Sample size and power determination for stratified clinical trials. J Stat Comp Simul 8 (1978) 65-73
18. Dahlstrand H., Näsman A., Romanitan M., et al. Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 28 (2008) 1133-1138
19. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV Titer, Bcl-xL and p-53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26 (2008) 3128-3137
20. Smith B.D., Smith G.L., Carter D., et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 780-785
21. Chang B.W., Kim D.H., Kowalski D.P., et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 10 (2004) 1678-1684
22. Wei Q., Sheng L., Shui Y., et al. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15 (2008) 1193-1201
23. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
24. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944